C. PrempunpongL. F. ChalakJ. GarfinkleB. ShahV. KalraN. RollinsR. BoyleK. A. NguyenI. MirA. PappasP. MontaldoS. ThayyilP. J. SánchezS. ShankaranA. R. LaptookG. Sant'annaUT Southwestern Medical CenterImperial College LondonMahidol UniversityBrown UniversityWayne State UniversityCentre universitaire de santé McGillOhio State University2019-08-282019-08-282018-01-01Journal of Perinatology. Vol.38, No.1 (2018), 80-8514765543074383462-s2.0-85040818903https://repository.li.mahidol.ac.th/handle/20.500.14594/47234© 2018 Nature America, Inc., part of Springer Nature. All rights reserved. Objective:To determine short-term outcomes of infants with evidence of hypoxia-ischemia at birth and classified as mild neonatal encephalopathy (NE) at <6 h of age.Study Design:Prospective multicenter study. Mild NE was defined as 3/41 abnormal category in modified Sarnat score. Primary outcome was any abnormality on early amplitude integrated electroencephalogram (aEEG) or seizures, abnormal brain magnetic resonance imaging (MRI) or neurological exam at discharge.Results:A total of 54/63 (86%) of enrolled infants had data on components of the primary outcome, which was abnormal in 28/54 (52%): discontinuous aEEG (n=4), MRI (n=9) and discharge exam (n=22). Abnormal tone and/or incomplete Moro were the most common findings. MRI abnormalities were confined to cerebral cortex but two infants had basal ganglia and/or thalamus involvement. The 18 to 24 months follow-up is ongoing.Conclusions:A larger than expected proportion of mild NE infants with abnormal outcomes was observed. Future research should evaluate safety and efficacy of neuroprotection for mild NE.Mahidol UniversityMedicineReviewSCOPUS10.1038/jp.2017.164